- Home
- HFFG vs ZNTL Comparison
HFFG vs ZNTL Comparison
Compare HFFG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | ZNTL |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.7M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HFFG | ZNTL |
|---|---|---|
| Price | $2.60 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 77.9K | ★ 494.2K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,541,000.00 | $26,865,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $1.01 |
| 52 Week High | $4.93 | $3.53 |
Technical Indicators
Market Signals| Indicator | HFFG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 49.05 |
| Support Level | $2.54 | $1.34 |
| Resistance Level | $2.79 | $1.45 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 55.67 | 52.94 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.